Kati Copley-Merriman, MS, MBA, is Vice President of the Outcomes group at RTI Health Solutions. Ms. Copley-Merriman has more than 25 years of industry experience, including leadership roles in Global Outcomes Research at Eli Lilly, Parke-Davis, and Pfizer. She has experience in all aspects of outcomes research (OR), including clinical trial design with patient-reported outcomes endpoints, economic evaluations, OR strategic plans, and regulatory strategy.
In her RTI-HS role, Ms. Copley-Merriman leads a team of scientists, reimbursement experts, and medical writers responsible for developing OR strategic plans, literature reviews, disease state summaries, and product value and reimbursement dossiers, and for conducting qualitative payer research. Ms. Copley-Merriman has experience in many therapeutic areas, including oncology, pain and inflammation, dermatology, respiratory, urology, and central nervous system. Ms. Copley-Merriman is an active member of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and was elected to the ISPOR Board for 2010 to 2012. Ms. Copley-Merriman also was appointed to be member of the Value in Health editorial advisory board for November 2014 to November 2018.
Visit the RTI Health Solutions website to learn about our Market Access and Outcomes Strategy services.